{
    "id": 17210,
    "fullName": "PPM1D amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PPM1D amplification indicates an increased number of copies of the PPM1D gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8493,
        "geneSymbol": "PPM1D",
        "terms": [
            "PPM1D",
            "IDDGIP",
            "JDVS",
            "PP2C-DELTA",
            "WIP1"
        ]
    },
    "variant": "amp",
    "createDate": "01/25/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20329,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FK866 treatment inhibited viability of a breast cancer cell line harboring PPM1D amplification in culture (PMID: 31439867).",
            "molecularProfile": {
                "id": 17703,
                "profileName": "PPM1D amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17806,
                    "pubMedId": 31439867,
                    "title": "PPM1D mutations silence NAPRT gene\u00a0expression and confer NAMPT inhibitor sensitivity in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31439867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5036,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 treatment, which requires an intact P53 response, inhibited the growth of a breast cancer cell line harboring PPM1D amplification and TP53 wild-type (PMID: 24390428).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4845,
                    "pubMedId": 24390428,
                    "title": "Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24390428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5039,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of RG7388 treatment in TP53 wild-type breast cancer cells harboring PPM1D amplification resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3737,
                "therapyName": "GSK2830371 + Idasanutlin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5038,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of Nutlin-3 treatment in TP53 wild-type breast cancer cells harboring PPM1D amplification resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3736,
                "therapyName": "GSK2830371 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5040,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of Nutlin-3 treatment in TP53 wild-type colorectal cancer cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3736,
                "therapyName": "GSK2830371 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5037,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 treatment, which requires an intact P53 response, had no effect on a breast cancer cell line co-harboring PPM1D amplification and a TP53 mutation (PMID: 24390428).",
            "molecularProfile": {
                "id": 20119,
                "profileName": "PPM1D amp TP53 mut"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 3459,
                "name": "breast carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4845,
                    "pubMedId": 24390428,
                    "title": "Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24390428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17703,
            "profileName": "PPM1D amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7685,
                    "name": "PPM1D Inhibitor",
                    "profileName": "PPM1D amp"
                }
            ]
        },
        {
            "id": 20109,
            "profileName": "PPM1D amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20119,
            "profileName": "PPM1D amp TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}